業績（2023年）

Publications

1. Baba Y, Nakamaki T, Sakai H, Fukuchi K, Kabasawa N, Hattori N, Harada H. Chronic neutrophilic leukemia preceded by myelodysplastic syndromes. Int J Hematol. 2023; 118(5): 636-641.

2. Shima M, Amano K, Ogawa Y, Yoneyama K, Ozaki R, Kobayashi R, Sakaida E, Saito M, Okamura T, Ito T, Hattori N, Higasa S, Suzuki N, Seki Y, Nogami K. A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A. J Thromb Haemost. 2023;21(3):534-545.

3. Yonezawa R, Shimamoto K, Kabasawa N, Sano M, Tanaka S, Matsui M, Harada H, Sunaga T. A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma. Leuk Res Rep. 2023; 19: 100365.

4. Suzuki A, Yamaguchi F, Maeda M, Hashiguchi M, Kabasawa N, Sasaki J, Sato T, Fuyama M, Yamazaki Y, Endo K, Iwata K, Kobayashi S, Fujihara H. Antimicrobial Stewardship Program for Patients in the Hematological Department Receiving Carbapenem Therapy: A Single-Center and Interrupted Time Series Analysis. Antibiotics (Basel). 2023; 12(2): 302.

5. Baba Y, Sakai H, Kabasawa N, Harada H. Successful Treatment of an Aggressive Adult T-cell Leukemia/Lymphoma with Strong CD30 Expression Using Brentuximab Vedotin as Combination and Maintenance Therapy. Intern Med. 2023; 62(4): 613-616.

6. Sasaki Y, Murai S, Okamura R, Uesugi Y, Shimada S, Watanuki M, Fujiwara S, Kawaguchi Y, Arai N, Yanagisawa K, Honma M, Yamochi T, Hattori N. CD5- and CD10-positive MYC and BCL2 double-expressor diffuse large B-cell lymphoma with MYD88L265P mutation: a case report and literature review. Rinsho Ketsueki. 2023;64(1):42-48. Japanese.